Sign in

CIK 0001582313

  • Large accelerated filer

Xenon Pharmaceuticals Inc.

Sign in to watch
Ticker
XENE
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
British Columbia, Canada
Entity type
Operating
EIN
980661854
Phone
+1 604-484-3300
Business address
200 - 3650 GILMORE WAY, BURNABY, British Columbia, Canada
Open-market buys, last 90 days
$1,681,140
in 2 filings
Open-market sales, last 90 days
$425,829
in 1 filing, $426K under 10b5-1 plans

Net +$1,255,311. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2022-03-07 EMPFIELD JAMES R. EVP, Drug Discovery Exercise or conversion · Stock Option (Right to Buy) −2,500 0
2022-03-07 EMPFIELD JAMES R. EVP, Drug Discovery Exercise or conversion · Stock Option (Right to Buy) −40,000 0
2022-03-04 PIMSTONE SIMON N. Director Exercise or conversion +10,288 $3.67 $38K 220,474
2022-03-04 PIMSTONE SIMON N. Director Shares withheld for taxes −963 $31.42 $30K 219,511
2022-03-04 PIMSTONE SIMON N. Director Sale −4,532 $30.66 $139K 214,979
2022-03-04 PIMSTONE SIMON N. Director Sale −4,793 $30.56 $146K 210,186
2022-03-04 PIMSTONE SIMON N. Director Exercise or conversion · Stock Option (Right to Buy) −10,288 0
2022-03-04 ROBIN SHERRINGTON EVP, Strategy & Innovation Exercise or conversion +1,234 $3.67 $5K 33,466
2022-03-04 ROBIN SHERRINGTON EVP, Strategy & Innovation Shares withheld for taxes −696 $31.42 $22K 32,770
2022-03-04 ROBIN SHERRINGTON EVP, Strategy & Innovation Exercise or conversion +6,172 $3.67 $23K 38,942
2022-03-04 ROBIN SHERRINGTON EVP, Strategy & Innovation Sale −6,710 $30.56 $205K 32,232
2022-03-04 ROBIN SHERRINGTON EVP, Strategy & Innovation Sale −5,000 $30.15 $151K 27,232
2022-03-04 ROBIN SHERRINGTON EVP, Strategy & Innovation Sale −5,000 $31.05 $155K 22,232
2022-03-04 ROBIN SHERRINGTON EVP, Strategy & Innovation Sale −5,000 $30.23 $151K 17,232
2022-03-04 ROBIN SHERRINGTON EVP, Strategy & Innovation Exercise or conversion · Stock Option (Right to Buy) −1,234 0
2022-03-04 ROBIN SHERRINGTON EVP, Strategy & Innovation Exercise or conversion · Stock Option (Right to Buy) −6,172 0
2022-03-04 EMPFIELD JAMES R. EVP, Drug Discovery Exercise or conversion +25,000 $8.40 $210K 35,000
2022-03-04 EMPFIELD JAMES R. EVP, Drug Discovery Shares withheld for taxes −6,685 $31.42 $210K 28,315
2022-03-04 EMPFIELD JAMES R. EVP, Drug Discovery Sale −18,315 $30.79 $564K 10,000
2022-03-04 EMPFIELD JAMES R. EVP, Drug Discovery Exercise or conversion · Stock Option (Right to Buy) −25,000 0

Page 18 of 27 · 536 trades